Drugs / Decavac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00393276 | Aug 2007 → Jul 2009 | HIV infectious disease, hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00835237 Comparator | Feb → Jul 2009 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00457249 Comparator | Mar 2007 → Sep 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DECAVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00457249 ↗ |
| Modality | Vaccine | “Diphtheria and tetanus toxoid vaccine” NCT00393276 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00457249 ↗ |